A 46-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS
- Registry ID
- RLM-MD-03
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ALLERGAN INC
- Start date
- 2018-11-05
- Completion date
- 2020-09-18
- Last update
- 2018-05-14
Conditions
- TYPE 2 DIABETES
- TYPE 1 DIABETES
- DIABETIC GASTROPARESIS
Related clinical trials
- A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ELECOGLIPRON COMPARED WITH ORAL SEMAGLUTIDE IN ADULTS WITH TYPE 2 DIABETES MELLITUS (ELUMINATE-2)
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY RO7795068 ADMINISTERED TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES
- EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED, ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED TRIAL (VESPER-5)
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BARICITINIB TO PRESERVE BETA CELL FUNCTION IN PARTICIPANTS NEWLY DIAGNOSED WITH TYPE 1 DIABETES AGED =1 TO <36 YEARS. (BARICADE-PRESERVE)
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BARICITINIB TO DELAY STAGE 3 TYPE 1 DIABETES IN AT-RISK PARTICIPANTS AGED =1 TO <36 YEARS (BARICADE-DELAY)
- EFFICACY AND SAFETY OF CAGRILINTIDE FOR WEIGHT MANAGEMENT IN PARTICIPANTS
WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (RENEW 2)
View on source registry